清肺排毒汤治疗轻型/普通型新型冠状病毒肺炎295例多中心临床研究  

Qingfei Paidu Decoction(清肺排毒汤)for Treatment of Mild/Moderate COVID-19 in 295 Cases:A Multi-Centered

作　　者：孙易娜[1] 吕文亮[1] 李昊[1] 肖勇[1] 杨旻[1] 杨海军[1] 高清华[1] 杨忠奇[2] 寿折星[3] 胡家才[4] 马永刚[4] 罗正武 程冰洁 刘林[1] 沈峰[1] 张思依 刘之义 徐晓惠 赵政 张涵灵 龙喻 梅青青 史瑞雯 刘海根 SUN Yina;LYU Wenliang;LI Hao;XIAO Yong;YANG Min;YANG Haijun;GAO Qinghua;YANGZhongqi;SHOU Zhexing;HU Jiacai;MA Yonggang;LUO Zhengwu;CHENG Bingjie;LIU Lin;SHEN Feng;ZHANG Siyi;LIU Zhiyi;XU Xiaohui;ZHAO Zheng;ZHANG Hanling;LONG Yu;MEIQingqingi;SHI Ruiwen;LIU Haigen(Hubei University of Chinese Medicine,Wuhan,430061;The First Affiliated Hospital of Guangzhou University of Chinese Medicine;Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology;Renmin Hospital of Wuhan University;Wuhan Xinzhou District Peoples Hospital;The Third Peoples Hospital of Hubei Province)

机构地区：[1]湖北中医药大学,湖北省武汉市430061 [2]广州中医药大学第一附属医院 [3]华中科技大学同济医学院附属协和医院 [4]武汉大学人民医院 [5]武汉市新洲区人民医院 [6]湖北省第三人民医院

出　　处：《中医杂志》2021年第7期599-603,共5页Journal of Traditional Chinese Medicine

基　　金：国家重点研发计划“公共安全风险防控与应急技术装备”重点专项(2020YFC0845300)。

摘　　要：目的观察清肺排毒汤治疗新型冠状病毒肺炎轻型/普通型的临床疗效。方法收集2020年2月5日至3月10日在武汉市5家方舱医院治疗的新型冠状病毒肺炎轻型/普通型患者295例,根据治疗方案分为清肺排毒汤组199例和联合用药组96例。清肺排毒汤组仅给予清肺排毒汤口服治疗,每日1剂;联合用药组在口服清肺排毒汤基础上联合西药或中成药治疗。比较两组患者住院期间重症/危重症转化情况、平均住院时间、核酸转阴时间、临床主要症状(包括发热、咳嗽、咯痰、咽痛、乏力、头痛、腹泻、憋闷)改善情况及胸部CT影像学改善情况。结果两组患者住院期间均无重症/危重症转化者。清肺排毒汤组患者住院中位时间为9.0(7.0~12.0)天,核酸转阴中位时间为5.0(3.0~9.0)天;联合用药组分别为16.0(11.0~22.0)天、10.0(7.0~14.0)天,两组比较差异均有统计学意义(P<0.05)。清肺排毒汤组患者咯痰消失时间短于联合用药组(P<0.05),而其他主要症状消失时间差异无统计学意义(P>0.05)。清肺排毒汤组患者胸部CT吸收率为95.0%(153/161),联合用药组为91.2%(83/91),差异有统计学意义(P<0.05)。结论清肺排毒汤单独使用能促进轻型/普通型新型冠状病毒肺炎患者核酸转阴、胸部CT及咯痰症状的改善,缩短住院时间,较药物联用方案具有一定优势。Objective To explore the effects of Qingfei Paidu Decoction(QFPDD,清肺排毒汤)in the treatment of mild/moderate cases of coronavirus disease 2019(COVID-19).Methods A total of 295 mild/moderate cases of COVID-19 admitted to five Wuhan mobile cabin hospitals from February 5 th to March 10 th,2020 were included,and divided into QFPDD group(199 cases)and combination group(96 cases)according to the treatment therapies.QFPDD,one dose daily,was orally administered in QFPDD group,while western medicine and Chinese patent medicine in addition to QFPDD were given in combination group.Rate of disease progression into severe/critically severe cases,average length of hospitalization,improvement of clinical symptoms including fever,cough,expectoration,sore throat,fatigue,headache,diarrhea,suffocation and CT imaging were assessed.Results No cases in both groups were found to progress into severe or critically severe disease.The median hospitalization length and nucleic acid negative conversion time were 9 days(7-12 days)and 5 days(3-9 days)in the QFPDD group,while those in the combination group were 16 days(11-22 days)and 10 days(7-14 days),with significantly differences between groups(P<0.05).The disappearance time of expectoration in the QFPDD group was significantly shorter than that in the combination group(P<0.05),while there were no significant differences in the disappearance time of other main symptoms between groups(P>0.05).The chest CT absorption rate in the QFPDD group was 95.0%(153/161),and that of the combination group was 91.2%(83/91);the difference between groups was statistically significant(P<0.05).Conclusion QFPDD alone can promote negative conversion of nucleic acid,improve chest CT and expectoration symptoms,and shorten the length of hospitalization for treating mild/moderate cases of COVID-19,having certain advantages over drug combination treatment.

关 键 词：新型冠状病毒肺炎 清肺排毒汤 住院时间 核酸转阴 CT影像学 

分 类 号：R259[医药卫生—中西医结合]